This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Neurim Pharmaceuticals Ltd.
Drug Names(s): Neu-120
Description: Neu-120, has been developed as adjunct therapy to levodopa in patients with motor fluctuations and in patients who do not tolerate optimal doses of levodopa. It is a selective uncompetitive NMDA receptor modulator aimed at improving motor control and reducing levodopa-induced dyskinesia.
It also inhibits MAO-B and GSK-3B activities in vitro. It is expected to help to alleviate the symptoms of parkinsonism, and at the same time reduce severity or abolish drug-induced extrapyramidal reactions including dyskinesia that are associated with such increase.
Pink Sheet FDA Performance Tracker: User Fee Goal Dates
Pink Sheet Weekly Trademark Review Oct. 27, 2015
Additional information available to subscribers only: